Lantheus Holdings
Lantheus Holdings

Lantheus Holdings

Pharmaceuticals
WebsiteInvestor RelationsSEC
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

$6.6B

Market Cap • 9/11/2026

2007

(19 years)

Founded

2015

(11 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

5

P/S

4,2

P/EBITDA

16,8

P/OCF

15,9

P/FCF

16,9

P/E

24,3

BVPS

19,6

EPS

4,1

Market Cap

Market Cap

6,6B

EV

6,5B

EV/Revenue

4,2

EV/EBITDA

16,7

EV/EBIT

21,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

2,8%

Total Yield

2,8%

Payout

0%

Retained Earnings

873M

Profitability

Gross Margin

60,1%

EBITDA Margin

25,1%

EBIT Margin

19,4%

Net Margin

17,7%

D&A/EBITDA

0%

R&D/Revenue

11,1%

Capex/Revenue

1,6%

Capex/D&A

28,2%

Capex/OCF

6%

SBC/OCF

18,9%

% PPE

6,3%

% Goodwill

9,9%

ROE

22,2%

ROIC

15,4%

Growth

CAGR Revenue 5Y

32,8%

CAGR OCF 5Y

55,9%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

3,1

Quick Ratio

2,8

Interest Coverage

1526,4%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium